Most of the presentations at SABCS focus on the latest clinical and basic research results relating to breast cancer. By contrast, educational sessions are designed to inform and update those interested in a review on a particular topic. Although these sessions may include new specific research findings, their primary intent is to offer summaries of existing knowledge, and to provide background for some of the active areas which will be discussed in the rest of the meeting.

Multidisciplinary Approach to Optimizing Local Regional Therapy in Hormone Receptor Positive Breast Cancer
Moderator: Armando Giuliano, MD
Cedars-Sinai Medical Center
Los Angeles, CA

Neoadjuvant therapy for hormone receptor positive breast cancer: Challenges and advances 
Otto Metzger, MD
Dana-Farber Cancer Institute,
Boston, MA

Surgical management of the upfront surgery patient
Melissa L. Pilewskie, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Local regional therapy considerations after preoperative therapy in hormone receptor positive breast cancer
Tari Ann King, MD
Dana-Farber Cancer Institute
Brigham and Women's Cancer Center
Boston, MA

Tailoring Adjuvant Therapies Based on Neoadjuvant Response
Moderator: Charles E. Geyer, MD
Virginia Commonwealth University
Massey Cancer Center
Richmond, VA

The biology and plasticity of residual disease
Charles M. Perou, PhD
University of North Carolina
Chapel Hill, NC

Neoadjuvant treatment: Tailoring response by subtype
Jenny C. Chang, MD
Houston Methodist Hospital
Houston, TX

Local regional treatment in patients who achieve pathologic complete response
Julia White, MD
The Ohio State University
Columbus, OH

Targeted Treatment Beyond PARP1 Inhibition
Moderator: Alexander Bishop, DPhil
Greehey Children's Cancer Research Institute
UT Health San Antonio
San Antonio, TX

Clinical indications of PARP1 inhibitors and other targets
Melinda L. Telli, MD
Stanford University Medical Center
Stanford, CA

Novel DNA repair targets for breast cancer
Thomas Helleday, PhD
University of Sheffield
Sheffield, UNITED KINGDOM

Clinically relevant biomarkers of PARP1 inhibitor resistance and indicators of targeted combinatorial treatments 
Violeta Serra, PhD
Vall d'Hebron Institute of Oncology
Barcelona, SPAIN

Implementation of Genetic Testing in Breast Cancer Patients
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

Genetic testing for hereditary breast cancer: Who should be tested?  
Nadine Tung, MD
Beth Israel Deaconess Medical Center
Boston, MA

Alternativepractical models for genetic services in the era of increased demand 
Banu Arun, MD
University of Texas MD Anderson Cancer Center
Houston, TX

Breast cancer genetic testing: moving from cancer risk assessment to therapeutic biomarker
Judith Balmaña, MD, PhD
Vall d'Hebron University Hospital
Barcelona, SPAIN

Acquired Endocrine Therapy Resistance Beyond ESR1 Mutations
Moderator: Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX

Adaptive resistance to hormonal therapy
Suzanne A.W. Fuqua, PhD
Baylor College of Medicine
Houston, TX

Exploiting single cell transcriptome analyses to track adaptation to endocrine therapies
Luca Magnani, PhD
Imperial College London 
London, UNITED KINGDOM

The genomic landscape of endocrine-resistant metastatic breast cancer
Pedram Razavi, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Breast Cancer Prevention
Moderator: Judy E. Garber, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Targeted approach to breast cancer surveillance in high risk women: Update of the newest technologies and how to use them
Maxine S. Jochelson, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Risk-based recommendations: considering the time-frame
Seema A. Khan, MD
Northwestern University
Chicago, IL

Low dose tamoxifen and other approaches to improve chemoprevention uptake  
Andrea De Censi, MD
E.O. Ospedali Galliera 
Genova, ITALY

Evolving Opportunities to Personalize Radiation Decisions
Moderator: Reshma Jagsi, MD, DPhil
University of Michigan
Ann Arbor, MI

Guiding decisions to omit radiotherapy after breast-conserving surgery for DCIS. Can genomic biomarkers help?   
Eileen Rakovitch, MD, MSc, FRCPC
Sunnybrook Health Sciences Centre
Toronto, CANADA

Guiding decisions to omit radiation after breast conserving surgery for invasive breast cancer
Corey Speers MD, PhD
University of Michigan
Ann Arbor, MI

Guiding selection of RT approach after lumpectomy
Simona Shaitelman, MD
University of Texas MD Anderson Cancer Center 
Houston, TX

Conversations on Tough Topics Surrounding Cancer Care
Moderator: Susan Rafte
Community Advocate, Baylor College of Medicine Breast Center
Houston, TX

Progression of disease and end of life: How to break bad news
Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Challenging conversations: The toll on healthcare providers
Sharon H. Giordano, MD, MPH, FASCO
University of Texas MD Anderson Cancer Center
Houston, TX

The financial costs and burden of breast cancer care
Rachel A. Greenup, MD, MPH
Duke Cancer Institute
Durham, NC

Panel Discussion

Immunotherapy For Triple –Negative Breast Cancer
Moderator: Sylvia Adams, MD
NYU Langone Health
New York, NY

Immunotherapy in metastatic and neoadjuvant breast cancer
Rita Nanda, MD
University of Chicago
Chicago, IL

Detecting and managing IO related toxicities wisely
Peter Schmid, MD, PhD
Barts Cancer Institute
London, UNITED KINGDOM

Assessment of PD-L1/PD-1: If, when, why and how
David L. Rimm, MD, PhD
Yale University School of Medicine
New Haven, CT

Breast Cell Fate Control and Plasticity
Moderator: Yi Li, PhD
Baylor College of Medicine
Houston, TX

Cell fate and plasticity in the mammary gland
Cédric Blanpain, MD, PhD
Universite Libre de Bruxelles
Bruxelles, BELGIUM

Deconstructing breast cancer from a developmental perspective
Geoffrey Wahl, PhD
Salk Institute for Biological Studies
La Jolla, CA

Cell fate plasticity during breast cancer development -where is the translational utility?
Christina Scheel, MD
Helmholtz Center Munich
Institute of Stem Cell Research
Neuherberg, GERMANY

Endocrine Therapy 2020
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

Adjuvant endocrine therapy in 2020: It's complicated
Angelo Di Leo, MD, PhD
Hospital of Prato 
Prato, ITALY

Endocrine therapy beyond 2020 (metastatic, new agents)
Erica L. Mayer, MD, MPH
Dana-Farber Cancer Institute
Harvard Medical School 
Boston, MA

Everything comes with a price (toxicity)
Dawn Hershman, MD
Columbia University Medical Center
New York Presbyterian Hospital
New York, NY 

Discussing Risk in the Context of GEP Testing
Moderator: Lesley Fallowfield, BSc, DPhil
Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
Brighton & Sussex Medical School
Brighton, UNITED KINGDOM

TBA
Lesley Fallowfield, BSc, DPhil
Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
Brighton & Sussex Medical School
Brighton, UNITED KINGDOM

TBA
Valerie Ann Jenkins, DPhil, BSc
Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
Brighton & Sussex Medical School
Brighton, UNITED KINGDOM

The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the 2019 SABCS. Space in the workshop is limited. Preregistration is not required.                                                                                                                             

Mastectomy should not be offered to patients who are breast conservation candidates when modern radiotherapy is available
Chairman: Richard Crownover, MD, PhD
UT Health San Antonio
San Antonio, TX

             For
             Lawrence B. Marks, MD, FASTRO
             University of North Carolina at Chapel Hill School of Medicine
             Chapel Hill, NC

             Against
             Alastair M. Thompson, ALCM, BSc(Hons), MBChB, MD,
             FRCSEd(Gen)
             Baylor College of Medicine
             Houston, TX

PRELIMINARY SCHEDULE